OPTR News

Optimer Pharmaceuticals, which is developing antibiotics to treat gastrointestinal diseases, priced an initial public offering of 7 million shares at $7, below its downwardly revised range of $8 to $9, on Thursday night. The original range on the deal was $12...read more

Optimer Pharmaceuticals a developer of antibiotics intended to treat gastrointestinal disorders, lowered its range Thursday morning from $12-$14 to $8-$9. The company still plans to sell 5.25 million shares. Joint book runners Piper Jaffray and Jefferies plan ...read more

Optimer Pharmaceuticals, which is developing anti-infective products, announced on Monday that it plans to offer 5.25 million shares in its IPO. The San Diego-based company plans to issue the shares at a range of $12-$14, which gives it a proposed market cap...read more

Optimer Pharmaceuticals, a biotech developing anti-infective products, filed for an IPO on Thursday. Piper Jaffray and Jefferies & Company are set to manage the deal for the San Diego-based company. Terms and timing have yet to be announced....read more